Bone tissue engineering: Recent advances and promising therapeutic agents

Expert Opinion on Biological Therapy

Volumn 3, Issue 3, 2003, Pages 409-423

  Jadlowiec, Julie A ^b   Celil, Ayse B ^b   Hollinger, Jeffrey O ^a  

^a CARNEGIE MELLON UNIVERSITY   (United States)

^b NONE

Author keywords

Biomaterials; Bone; Signalling molecules; Tissue engineering; Transcription factors

Indexed keywords

BIOMATERIAL; BONE MORPHOGENETIC PROTEIN; FIBROBLAST GROWTH FACTOR; GROWTH FACTOR; INORGANIC COMPOUND; POLYMER; SOMATOMEDIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR OSX; TRANSCRIPTION FACTOR RUNX2; UNCLASSIFIED DRUG; VASCULOTROPIN;

BONE DEVELOPMENT; BONE REGENERATION; BONE REMODELING; BONE TISSUE; CELL DIFFERENTIATION; COMPOSITE MATERIAL; EXTRACELLULAR MATRIX; FRACTURE HEALING; HUMAN; OSTEOBLAST; REVIEW; SIGNAL TRANSDUCTION; TISSUE ENGINEERING;

ANIMALS; BONE AND BONES; BONE REGENERATION; GROWTH SUBSTANCES; HUMANS; TISSUE ENGINEERING;

EID: 0037526655     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/eobt.3.3.409.21183     Document Type: Review

References (164)

1. LANGER R, VACANTI JP: Tissue engineering. Science (1993) 260:920-926.
2. GRIFFITH LG, NAUGHTON G: Tissue engineering-current challenges and expanding opportunities. Science (2000) 295:1009-1016.
3. RAO MS, MATTSON MP: Stem cells and aging: expanding the possibilities. Mech. Ageing Dev. (2001) 122(7):713-734.
4. PRAEMER A, FURNER S, RICE DP: Musculoskeletal conditions in the United States. American Academy of Orthopaedic Surgeons, Parkridge, IL, USA (1992).
5. ROSE FRA, OREFFO ROC: Bone tissue engineering: hope versus hype. Biochem. Biophys. Res. Commun. (2002) 292:1-7.
6. LUDWIG SC, KOWALSKI JM, BODEN SD: Osteoinductive bone graft substitutes. Eur. Spine J. (2000) 9(Suppl. 1):S119-S125.
7. DAMSKY CH, WERB Z: Signal transduction by integrin receptors for extracellular matrix: cooperative processing of extracellular information Curr. Opin. Cell Biol. (1992) 4(5):772-781. Key paper that discusses potential synergistic actions of various extracellular signals on intracellular events.
8. GIANCOTTI FG, RUOSLAHTI E: Integrin signaling. Science (1999) 285(5430):1028-1032.
9. XIAO G, GOPALAKRISHNAN R, JIANG D et al.: Bone morphogenetic proteins, extracellular matrix, and mitogen-activated protein kinase signaling pathways are required for osteoblast-specific gene expression and differentiation in MC3T3-E1 cells. J. Bone Miner. Res. (2002) 17(1):101-110.
10. CANALIS E, RYDZIEL S, DELANY AM, VARGHESE S, JEFFREY JJ: Insulin-like growth factors inhibit interstitial collagenase synthesis in bone cell cultures. Endocrinology (1995) 136(4):1348-1354.
11. TRIPPEL SB: Potential role of insulinlike growth factors in fracture healing. Clin. Orthop. (1998) (355 Suppl.):S301-S313.
12. ROSEN CJ, DONAHUE LR, HUNTER SJ: Insulin-like growth factors and bone: the osteoporosis connection. Proc. Soc. Exp. Biol. Med. (1994) 206(2):83-102.
13. ZAPF J, SCHOENLE E, FROESCH ER: Insulin-like growth factors I and II: some biological actions and receptor binding characteristics of two purified constituents of nonsuppressible insulin-like activity of human serum. Eur. J. Biochem. (1978) 87(2);285-296.
14. MCCARTHY TL, JI C, CASINGHINO S, CENTRELLA M: Alternate signaling pathways selectively regulate binding of insulin-like growth Factor I and II on fetal rat bone cells. J. Cell. Biochem. (1998) 68(4):446-456.
15. OGATA N, CHIKAZU D, KUBOTA N et al.: Insulin receptor substrate-1 in osteoblast is indispensable for maintaining bone turnover. J. Clin. Invest. (2000) 105(7):935-943.
16. BOGUSLAWSKI G, HALE LV, YU XP et al.: Activation of osteocalcin transcription involves interaction of protein kinase A- and protein kinase C-dependent pathways. J. Biol. Chem. (2000) 275(2):999-1006.
17. THOMAS T, GORI F, SPELSBERG TC, KHOSLA S, RIGGS BL, CONOVER CA: Response of bipotential human marrow stromal cells to insulin-like growth factors: effect on binding protein production, proliferation, and commitment to osteoblasts and adipocytes. Endocrinology (1999) 140(11):5036-5044. Key paper that demonstrates effects of IGF-1 on cultures of bone marrow-derived human stem cells.
18. MOHAN S, JENNINGS JC, LINKHART TA, BAYLINK DJ: Primary structure of human skeletal growth factor: homology with human insulin-like growth factor-II. Biochim. Biophys. Acta (1988) 966(1):44-55.
19. ANDREW JG, HOYLAND J, FREEMONT AJ, MARSH D: Insulinlike growth factor gene expression in human fracture callus. Calcif. Tissue Int. (1993) 53(2):97-102.
20. BAK B, JORGENSEN PH, ANDREASSEN TT: Dose response of growth hormone on fracture healing in the rat. Acta Orthop. Scand. (1990) 61(1):54-57.
21. PFEILSCHIFTER J, OECHSNER M, NAUMANN A, GRONWALD RG, MINNE HW, ZIEGLER R: Stimulation of bone matrix apposition in vitro by local growth factors: a comparison between insulin-like growth Factor I, platelet-derived growth factor, and transforming growth factor beta. Endocrinology (1990) 127(1):69-75.
22. THALLER SR, DART A, TESLUK H: The effects of insulin-like growth factor-1 on critical-size calvarial defects in Sprague-Dawley rats. Ann. Plast. Surg. (1993) 31(5):429-433.
23. TANAKA H, QUARTO R, WILLIAMS S, BARNES J, LIANG CT: In vivo and in vitro effects of insulin-like growth factor-I (IGF-I) on femoral mRNA expression in old rats. Bone (1994) 15(6):647-653.
24. LEE CW, MARTINEK V, USAS A et al.: Muscle-based gene therapy and tissue engineering for treatment of growth plate injuries. J. Pediatr. Orthop. (2002) 22(5):565-572.
25. MADRY H, PADERA R, SEIDEL J et al.: Gene transfer of a human insulin-like growth Factor I cDNA enhances tissue engineering of cartilage. Hum. Gene Ther. (2002) 13(13):1621-1630.
26. KURTZ CA, LOEBIG TG, ANDERSON DD, DEMEO PJ, CAMPBELL PG: Insulin-like growth factor I accelerates functional recovery from Achilles tendon injury in a rat model. Am. J. Sports Med. (1999) 27(3):363-369.
27. KANDZIORA F, SCHMIDMAIER G, SCHOLLMEIER G et al.: IGF-I and TGF-beta1 application by a poly-(D,L-lactide)-coated cage promotes intervertebral bone matrix formation in the sheep cervical spine. Spine (2002) 27:1710-1723.
28. ILLI OE, FELDMANN CP: Stimulation of fracture healing by local application of humoral factors integrated in biodegradable implants. Eur. J. Pediatr. Surg. (1998) 8:251-255.
29. MEINEL L, ILLI OE, ZAPF J, MALFANTI M, MERKLE PM, GANDER B: Stabilizing insulin-like growth factor-I in poly(D,L-lactide-coglycolide). J. Control Release (2001) 70:193-202.
30. PITARU S, KOTEV-EMETH S, NOFF D et al.: Effect of basic fibroblast growth factor on the growth and differentiation of adult stromal bone marrow cells: enhanced development of mineralized bone-like tissue in culture. J. Bone Miner. Res. (1993) 8(8):919-929.
31. MANSUKHANI A, BELLOSTA P, SAHNI M, BASILICO C: Signaling by fibroblast growth factors (FGF) and fibroblast growth factor receptor 2 (FGFR2)-activating mutations blocks mineralization and induces apoptosis in osteoblasts. J. Cell Biol. (2000) 149(6):1297-1308.
32. XIAO G, JAING D, GOPALAKRISHNAN R, FRANCESCHI RT: FGF-2 induction of the osteocalcin gene requires MAPK activity and phosphorylation of the osteoblast transcription factor, Cbfa1/Runx2. J. Biol. Chem. (2002) 277:36181-36187.
33. CANALIS E, MCCARTHY TL, CENTRELLA M: Effects of platelet-derived growth factor on bone formation in vitro. J. Cell Physiol. (1989) 140(3):530-537.
34. JINGUSHI S, HEYDEMANN A, KANA SK, MACEY LR, BOLANDER ME: Acidic fibroblast growth factor (aFGF) injection stimulates cartilage enlargement and inhibits cartilage gene expression in rat fracture healing. J. Orthop. Res. (1990) 8(3):364-371.
35. RODAN SB, WESOLOWSKI G, THOMAS K, RODAN GA: Growth stimulation of rat calvaria osteoblastic cells by acidic fibroblast growth factor. Endocrinology (1987) 121(6):1917-1923.
36. RADOMSKY ML, THOMPSON AY, SPIRO RC, POSER JW: Potential role of fibroblast growth factor in enhancement of fracture healing. Clin. Orthop. (1998) 355(Suppl.):S283-S293.
37. BURGESS WH, MACIAG T: The heparin-binding (fibroblast) growth factor family of proteins. Ann. Rev. Biochem. (1989) 58:575-606.
38. BURGESS WH, DIONNE CA, KAPLOW J et al.: Characterization and cDNA cloning of phospholipase C-gamma, a major substrate for heparin-binding growth factor 1 (acidic fibroblast growth factor)-activated tyrosine kinase. Mol. Cell Biol. (1990) 10(9):4770-4777.
39. ORBAN JM, MARRA KG, HOLLINGER JO: Composition options for tissue-engineered bone. Tissue Eng. (2002) 8(4):529-539.
40. DUNSTAN CR, BOYCE R, BOYCE BF et al.: Systemic administration of acidic fibroblast growth factor (FGF-1) prevents bone loss and increases new bone formation in ovariectomized rats. J. Bone Miner. Res. (1999) 14:953-959.
41. PANDIT AS, FELDMAN DS, CAULFIELD J et al.: Stimulation of angiogenesis by FGF-1 delivered through a modified fibrin scaffold. Growth Factors (1998) 15(2):113-123.
42. KIMOTO T, HOSOKAWA R, KUBO T, MAEDA M, SANO A, AKAGAWA Y: Continuous administration of basic fibroblast growth factor (FGF-2) accelerates bone induction on rat calvaria-an application of a new drug delivery system. J. Dent. Res. (1998) 77:1965-1969.
43. INUI K, MAEDA M, SANO A et al.: Local application of basic fibroblast growth factor minipellet induces the healing of segmental bony defects in rabbits. Calcif. Tissue Intl. (1998) 63(6):490-495.
44. HOSOKAWA R, KIKUZAKI K, KIMOTO T et al.: Controlled local application of basic fibroblast growth factor (FGF-2) accelerates the healing of GBR. An experimental study in beagle dogs. Clin. Oral Implants Res. (2000) 11(4):345-353.
45. BATES DO, LODWICK D, WILLIAMS B: Vascular endothelial growth factor and microvascular permeability. Microcirculation (1999) 6(2):83-96.
46. ROBINSON CJ, STRINGER SE: The splice variants of vascular endothelial growth factor (VEGF) and their receptors. J. Cell Sci. (2001) 114(Pt 5):853-865.
47. BACIC M, EDWARDS NA, MERRILL MJ: Differential expression of vascular endothelial growth factor (vascular permeability factor) forms in rat tissues. Growth Factors (1995) 12(1):11-15.
48. POLTORAK Z, COHEN T, SIVAN R, et al.: VEGF145, a secreted vascular endothelial growth factor isoform that binds to extracellular matrix. J. Biol. Chem. (1997) 272(11):7151-7158.
49. COHEN T, GITAY-GOREN H, SHARON R et al.: VEGF121, a vascular endothelial growth factor (VEGF) isoform lacking heparin binding ability, requires cell-surface heparan sulfates for efficient binding to the VEGF receptors of human melanoma cells. J. Biol. Chem. (1995) 270(19):11322-11326.
50. SCHLESSINGER J, LAX I, LEMMON M: Regulation of growth factor activation by proteoglycans: what is the role of the low affinity receptors? Cell (1995) 83(3):357-360.
51. PARK, JE, KELLER GA, FERRARA N: The vascular endothelial growth factor (VEGF) isoforms: differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF. Mol. Biol. Cell (1993) 4(12):1317-1326.
52. FERRARA N, DAVIS-SMYTH T: The biology of vascular endothelial growth factor. Endocr. Rev. (1997) 18(1):4-25.
53. BAUTERS C, ASAHARA T, ZHENG LP et al.: Recovery of disturbed endothelium-dependent flow in the collateral-perfused rabbit ischemic hindlimb after administration of vascular endothelial growth factor. Circulation (1995) 91(11):2802-2809.
54. TAKESHITA S, PU LQ, STEIN LA et al.: Intramuscular administration of vascular endothelial growth factor induces dose-dependent collateral artery augmentation in a rabbit model of chronic limb ischemia. Circulation (1994) 90(5 Pt 2):II228-II234.
55. TAKESHITA S, TSURUMI Y, COUFFINAHL T et al.: Gene transfer of naked DNA encoding for three isoforms of vascular endothelial growth factor stimulates collateral development in vivo. Lab. Invest. (1996) 75(4):487-501.
56. TAKESHITA, S, ISSHIKI T, MORI H et al.: Microangiographic assessment of collateral vessel formation following direct gene transfer of vascular endothelial growth factor in rats. Cardiovasc. Res. (1997) 35(3):547-552.
57. STONE D, PHANEUF M, SIVAMURTHY N et al.: A biologically active VEGF construct in vitro: implications for bioengineering-improved prosthetic vascular grafts. J. Biomed. Mater. Res. (2002) 59(1):160-165.
58. FRERICH B, LINDEMANN N, KURTZ-HOFFMAN J et al.: In vitro model of a vascular stroma for the engineering of vascularized tissues. Int. J. Oral Maxillofac. Surg. (2001) 30(5):414-420.
59. PEPPER MS, FERRARA N, ORCI L et al.: Potent synergism between vascular endothelial growth factor and basic fibroblast growth factor in the induction of angiogenesis in vitro. Biochem. Biophys. Res. Commun. (1992) 189(2):824-831.
60. GOTO F, GOTO K, WEINDEL K, FOLKMAN J: Synergistic effects of vascular endothelial growth factor and basic fibroblast growth factor on the proliferation and cord formation of bovine capillary endothelial cells within collagen gels. Lab. Invest. (1993) 69(5):508-517.
61. NEHLS V, HERRMANN R, HUHNKEN M: Guided migration as a novel mechanism of capillary network remodeling is regulated by basic fibroblast growth factor. Histochem. Cell Biol. (1998) 109(4):319-329.
62. URIST MR: Bone: formation by autoinduction. Science (1965) 150(698):893-899.
63. LIEBERMAN JR, DALUISKI A, EINHORN TA: The role of growth factors in the repair of bone: biology and clinical applications. J. Bone Joint Surg. Am. (2002) 84:1032-1044.
64. RASCHKE M, WILDEMANN B, INDEN P et al.: Insulin-like growth factor-1 and transforming growth factor-beta1 accelerates osteotomy healing using polylactide-coated implants as a delivery system: a biomechanical and histological study in minipigs. Bone (2002) 30(1):144-151.
65. JOYCE ME, JINGUSHI S, BOLANDER ME: Transforming growth factor-beta in the regulation of fracture repair. Orthop. Clin. North Am. (1990) 21(1):199-209.
66. NODA M, CAMILLIERE JJ: In vivo stimulation of bone formation by transforming growth factor-beta. Endocrinology (1989) 124(6):2991-2994.
67. LIND M, SCHUMACKER B, SOBALLE K, KELLER J, MELSEN F, BUNGER C: Transforming growth factor-beta enhances fracture healing in rabbit tibiae. Acta Orthop. Scand. (1993) 64(5):553-556.
68. NIELSEN HM, ANDREASSEN TT, LEDET T, OXLUND H: Local injection of TGF-beta increases the strength of tibial fractures in the rat. Acta Orthop. Scand. (1994) 65(1):37-41.
69. CRITCHLOW MA, BLAND YS, ASHHURST DE: The effect of exogenous transforming growth factor-beta 2 on healing fractures in the rabbit. Bone (1995) 16(5):521-527.
70. CENTRELLA M, MCCARTHY TL, CANALIS E: Transforming growth factor-beta and remodeling of bone. J. Bone Joint Surg. Am. (1991) 73(9):1418-1428.
71. GOMBOTZ WR, PANKEY SC, BOUCHARD LS, RANCHALIS J, PUOLAKKAINEN P: Controlled release of TGF-beta 1 from a biodegradable matrix for bone regeneration. J. Biomater. Sci. Polym. Ed. (1993) 5(1-2):49-63.
72. ZHOU H, HAMMONDS RG, FINDLAY DM, MARTIN TJ, NG KW: Differential effects of transforming growth factor-beta 1 and bone morphogenetic protein 4 on gene expression and differentiated function of preosteoblasts. J. Cell Physiol. (1993) 155(1):112-119.
73. ASPENBERG P, JEPPSSON C, WANG JS, BOSTROM M: Transforming growth factor beta and bone morphogenetic protein 2 for bone ingrowth: a comparison using bone chambers in rats. Bone (1996) 19(5):499-503.
74. RIPAMONTI U, DUNEAS N, VAN DEN HEEVER B, BOSCH C, CROOKS J: Recombinant transforming growth factor-beta1 induces endochondral bone in the baboon and synergizes with recombinant osteogenic protein-1 (bone morphogenetic protein-7) to initiate rapid bone formation. J. Bone Miner. Res. (1997) 12(10):1584-1595.
75. HAN B, PERELMAN N, TANG B, HALL F, SHORS EC, NIMNI ME: Collagen-targeted BMP3 fusion proteins arrayed on collagen matrices or porous ceramics impregnated with Type I collagen enhance osteogenesis in a rat cranial defect model. J. Orthop. Res. (2002) 20(4):747-755.
76. BODEN SD, ZDEBLICK TA, SANDHU HS, HEIM SE: Use of recombinant human bone morphogenetic protein-2 to achieve posterolateral lumbar spine fusion in humans: a prospective, randomized clinical pilot trial: 2002 Volvo Award in clinical studies. Spine (2002) 27(23):2662-2673. Key paper in evaluating the efficacy of rhBMP-2 for clinical applications.
77. GOVENDER S, CSIMMA C, GENANT HK et al.: Recombinant human bone morphogenetic protein-2 for treatment of open tibial fractures: a prospective, controlled, randomized study of four hundred and fifty patients. J. Bone Joint Surg. Am. (2002) 84-A(12):2123-2134.
78. BODEN SD, ZDEBLICK TA, SANDHU HS, HEIM SE: The use of rhBMP-2 in interbody fusion cages. Definitive evidence of osteoinduction in humans: a preliminary report. Spine (2000) 25(3):376-381.
79. COCHRAN DL, JONES AA, LILLY LC, FIORELLINI JP, HOWELL H: Evaluation of recombinant human bone morphogenetic protein-2 in oral applications including the use of endosseous implants: 3-year results of a pilot study in humans. J. Periodontol. (2000) 71(8):1241-1257.
80. BARBOZA E, CAULA A, MACHADO F: Potential of recombinant human bone morphogenetic protein-2 in bone regeneration. Implant Dent. (1999) 8(4):360-367.
81. BREITBART AS, GRANDE DA, MASON JM, BARCIA M, JAMES T, GRANT RT: Gene-enhanced tissue engineering: applications for bone healing using cultured petiosteal cells transduced retrovirally with the BMP-7 gene. Ann. Plast. Surg. (1999) 42(5):488-495.
82. YASKO AW, LANE JM, FELLINGER EJ et al.: The healing of segmental bone defects, induced by recombinant human bone morphogenetic protein (rhBMP-2). A radiographic, histological, and biomechanical study in rats. J. Bone Joint Surg. Am. (1992) 74(5):659-670.
83. GERHART TN, KIRKER-HEAD CA, KRIZ MJ et al.: Healing segmental f femoral defects in sheep using recombinant human bone morphogenetic protein. Clin. Orthop. (1993) 293:317-326.
84. SCIADINI MF, JOHNSON KD: Evaluation of recombinant human bone morphogenetic protein-2 as a bone- graft substitute in a canine segmental defect model. J. Orthop. Res. (2000) 18(2):289-302.
85. BODEN SD, MARTIN GJ, HORTON WC, TRUSS TL, SANDHU HS: Laparoscopic anterior spinal arthrodesis with rhBMP-2 in a titanium interbody threaded cage. J. Spinal Disord. (1998) 11(2):95-101.
86. HOLLINGER JO, WINN S, BONADIO J: Options for tissue engineering to address challenges of the aging skeleton. Tissue Eng. (2000) 6(4):341-350.
87. JINGUSHI S, URABE K, OKAZAKI K et al.: Intramuscular bone induction by human recombinant bone morphogenetic protein-2 with beta-tricalcium phosphate as a carrier: in vivo bone banking for muscle-pedicle autograft. J. Orthop. Sci. (2002) 7(4):490-494.
88. BOYNE PJ, MARX RE, NEVINS M et al.: A feasibility study evaluating rhBMP-2/absorbable collagen sponge for maxillary sinus floor augmentation. Int. J. Periodontics Restorative Dent. (1997) 17(1):11-25.
89. POYNTON AR, LANE JM: Safety profile for the clinical use of bone morphogenetic proteins in the spine. Spine (2002) 27(16 Suppl. 1):S40-S48. Key paper that discusses and evaluates safety of rhBMP-2 in humans.
90. NOHE A, HASSEL S, EHRLICH M et al.: The mode of bone morphogenetic protein (BMP) receptor oligomerization determines different BMP-2 signaling pathways. J. Biol. Chem. (2002) 277(7):5330-5338.
91. GALLEA S, LALLEMAND F, ATFI A et al.: Activation of mitogen-activated protein kinase cascades is involved in regulation of bone morphogenetic protein-2-induced osteoblast differentiation in pluripotent C2C12 cells. Bone (2001) 28(5):491-498.
92. XIAO G, JIANG D, THOMAS P et al.: MAPK pathways activate and phosphorylate the osteoblast-specific transcription factor, Cbfa1. J. Biol. Chem. (2000) 275(6):4453-4459.
93. LAI CF, CHAUDHARY L, FAUSTO A et al.: Erk is essential for growth, differentiation, integrin expression, and cell function in human osteoblastic cells. J. Biol. Chem. (2001) 276(17):14443-14450. Key paper that shows the involvement of the MAPK signalling pathway in osteoblast differentiation.
94. HIGUCHI C, MYOUI A, HASHIMOTO N et al.: Continuous inhibition of MAPK signaling promotes the early osteoblastic differentiation and mineralization of the extracellular matrix. J. Bone Miner. Res. (2002) 17(10):1785-1794.
95. MIZUNO M, FUJISAWA M, KUBOKI Y: Type 1 collagen-induced osteoblastic differentiation of bone-marrow cells mediated by collagen-alpha2beta1 integrin interaction. J. Cell Physiol. (2000) 184(2):207-213.
96. NAKASHIMA K, ZHOU X, KUNKEL G et al.: The novel zinc finger-containing transcription factor osterix is required for osteoblast differentiation and bone formation. Cell (2002) 108(1):17-29. Key paper on the identification of Osx gene.
97. DUCY P, STARBUCK M, PRIEMEL M et al.: A Cbfa1-dependent genetic pathway controls bone formation beyond embryonic development. Genes Dev. (1999) 13(8):1025-1036. Key paper on the function of Cbfa1 (Runx2) gene.
98. OGAWA E, MARUYAMA M, KAGOSHIMA H et al.: PEBP2/PEA2 represents a family of transcription factors homologous to the products of the Drosophila runt gene and the human AML1 gene. Proc. Natl. Acad. Sci. USA (1993) 90:6859-6863.
99. XIAO ZS, LIU SG, HINSON TK, QUARLES LD: Characterization of the upstream mouse Cbfa1/Runx2 promoter. J. Cell Biochem. (2001) 82(4):647-659.
100. DRISSI H, LUC Q, SHAKOORI R et al.: Transcriptional autoregulation of the bone related CBFA1/RUNX2 gene. J. Cell Physiol. (2000) 184(3):341-350.
101. STEWART M, TERRY A, HU M et al.: Proviral insertions induce the expression of bone-specific isoforms of PEBP2alphaA (CBFA1): evidence for a new myc collaborating oncogene. Proc. Natl. Acad. Sci. USA (1997) 94(16):8646-8651.
102. MUNDLOS S, OTTOF, MUNDLOS C et al.: Mutations involving the transcription factor CBFA1 cause deidocranial dysplasia. Cell (1997) 89(5):773-779.
103. XIAO ZS, THOMAS R, HINSON TK, QUARLES LD: Genomic structure and isoform expression of the mouse, rat and human Cbfa1/Osf2 transcription factor. Gene (1998) 214(1-2):187-197.
104. SUDHAKAR S, KATZ MS, ELANGO N: Analysis of type-I and type-II RUNX2 protein expression in osteoblasts. Biochem. Biophys. Res. Commun. (2001) 286(1):74-79.
105. THIRUNAVUKKARASU K, MAHAJAN M, MCLARREN KW, STIFANI S, KARSENTY G: Two domains unique to osteoblast-specific transcription factor Osf2/Cbfa1 contribute to its transactivation function and its inability to heterodimerize with Cbfbeta. Mol. Cell Biol. (1998) 18(7):4197-4208.
106. FRENDO JL, XIAO G, FUCHS S, FRANCESCHI RT, KARSENTY G, DUCY P: Functional hierarchy between two OSE2 elements in the control of osteocalcin gene expression in vivo. J. Biol. Chem. (1998) 273(46):30509-30516.
107. DUCY P, ZHANG R, GEOFFROY V, RIDALL AL, KARSENTY G: Osf2/Cbfa1: a transcriptional activator of osteoblast differentiation. Cell (1997) 89(5):747-754. Key paper on the identification of Runx2 as a regulator of osteoblastic differentiation. Cell (1997) 89(5):747-754. Key paper on the identification of Runx2 as a regulator of osteoblastic differentiation.
108. OTTO F, THORNELL AP, CROMPTON T et al.: Cbfa1, a candidate gene for cleidocranial dysplasia syndrome, is essential for osteoblast differentiation and bone development. Cell (1997) 89(5):765-771.
109. TAKEDA S, BONNAMY JP, OWEN MJ et al.: Continuous expression of Cbfa1 in nonhypertrophic chondrocytes uncovers its ability to induce hypertrophic chondrocyte differentiation and partially rescues Cbfa1-deficient mice. Genes Dev. (2001) 15(4):467-481.
110. UETA C, IWAMOTO M, KANATANI N et al.: Skeletal malformations caused by overexpression of Cbfa1 or its dominant negative form in chondrocytes. J. Cell Biol. (2001) 153(1):87-100.
111. IWAMOTO M, KITAGAKI J, TAMAMURA Y et al.: Runx2 expression and action in chondrocytes are regulated by retinoid signaling and parathyroid hormone-related peptide (PTHrP). Osteoarthritis Cartilage (2003) 11(1):6-15.
112. GILBERT L, HE X, FARMER P et al.: Expression of the osteoblast differentiation factor RUNX2 (Cbfa1/AML3/Pebp2alpha A) is inhibited by tumor necrosis factor-alpha. J. Biol. Chem. (2002) 277(4):2695-2701.
113. JIMENEZ MJ, BALBIN M, ALVAREZ J et al.: A regulatory cascade involving retinoic acid, Cbfa1, and matrix metalloproteinases is coupled to the development of a process of perichondrial invasion and osteogenic differentiation during bone formation. J. Cell Biol. (2001) 155(7):1333-1344.
114. FRANCESCHI RT, XIAO G: Regulation of the osteoblast-specific transcription factor, Runx2: responsiveness to multiple signal transduction pathways. J. Cell Biochem. (2003) 88(3):446-454. A key reference describing Runx2 regulation.
115. HARTER LV, HRUSKA KA, DUNCAN RL: Human osteoblast-like cells respond to mechanical strain with increased bone matrix protein prodcution independent of hormonal regulation. Endocrinology (1995) 136:528-535.
116. ZIROS PG, GIL AP, GEORGAKOPOULOS T et al.: The bone-specific transcriptional regulator Cbfa1 is a target of mechanical signals in osteoblastic cells. J. Biol. Chem. (2002) 277(26):23934-23941.
117. SELVAMURUGAN N, PULUMATI MR, TYSON DR et al.: Parathyroid hormone regulation of the rat collagenase-3 promoter by protein kinase A-dependent transactivation of core binding factor alphal. J. Biol. Chem. (2000) 275(7):5037-5042.
118. XIAO ZS, HINSON TK, QUARLES LD: Cbfa1 isoform overexpression upregulates osteocalcin gene expression in non-osteoblastic and pre-osteoblastic cells. J. Cell. Biochem. (1999) 74:596-605.
119. BEERLI RR, DREIER B, BARBAS CF: Positive and negative regulation of endogenous genes by designed transcription factors. Proc. Natl. Acad. Sci. USA (2000) 97:1495-1501.
120. REBER EJ, HUANG Y, HICKEY R et al.: Induction of angiogenesis in a mouse model using engineered transcription factors. Nat. Med. (2002) 8:1427-1432.
121. HUTMACHER DW: Scaffolds in tissue engineering bone and cartilage. Biomaterials (2000) 21(24):2529-2543.
122. ZHANG, JY, BECKMAN EJ, HU J et al.: Synthesis, biodegradability, and biocompatibility of lysine diisocyanate-glucose polymers. Tissue Eng. (2002) 8(5):771-785.
123. DE GROOT J: Carriers that concentrate native bone morphogenetic protein in vivo. Tissue Eng. (1998) 4(4):337-341.
124. LI RH, WOZNEY JM: Delivering on the promise of bone morphogenetic proteins. Trends Biotechnol. (2001) 19(7):255-265.
125. BODEN SD: Bioactive factors for bone tissue engineering. Clin. Orthop. (1999) 367(Suppl.):S84-S594.
126. WANG S: Study on the mechanism of bone formation of bioactive materials BMP/Beta-TCP restoring bone defects by using quantitative analysis methods. Society for Biomaterials, 6th World Biomaterials Congress, Hawaii, USA (2000).
127. JIN QM, TAKITA H, KOHGO T et al.: Effects of geometry of hydroxyapatite as a cell substratum in BMP-induced ectopic bone formation. J. Biomed. Mater. Res. (2000) 51(3):491-499.
128. IJIRI S, NAKAMURA T, FUJISAWA Y et al.: Ectopic bone induction in porous apatite-wollastonite-containing glass ceramic combined with bone morphogenetic protein. J. Biomed. Mater. Res. (1997) 35(4):421-432.
129. WINN SR, ULUDAG H, HOLLINGER JO: Carrier systems for bone morphogenetic proteins. Clin. Orthop. (1999) 367(Suppl.):S95-S106.
130. WHANG K, GOLDSTICK TK, HEALY KE: A biodegradable polymer scaffold for delivery of osteotropic factors. Biomaterials (2000) 21(24):2545-2551.
131. LEE SC, SHEA M, BATTLE MA et al.: Healing of large segmental defects in rat femurs is aided by RhBMP-2 in PLGA matrix. J. Biomed. Mater. Res. (1994) 28(10):1149-1156.
132. HOLLINGER JO, LEONG K: Poly(alpha-hydroxy acids): carriers for bone morphogenetic proteins. Biomaterials (1996) 17(2):187-194.
133. LUCAS PA, LAURENCIN C, SYFTESTAD GT et al.: Ectopic induction of cartilage and bone by water-soluble proteins from bovine bone using a polyanhydride delivery vehicle. J. Biomed. Mater. Res. (1990) 24(7):901-911.
134. CLOKIE CM, URIST MR: Bone morphogenetic protein excipients: comparative observations on poloxamer. Plast. Reconstr. Surg. (2000) 105(2):628-637.
135. ZEGZULA HD, BUCK DC, BREKKE J et al.: Bone formation with use of rhBMP-2 (recombinant human bone morphogenetic protein-2). J. Bone Joint Surg. Am. (1997) 79(12):1778-1790.
136. SAITO N, OKADA T, TOBA S et al.: New synthetic absorbable polymers as BMP carriers: plastic properties of poly-D,L-lactic acid-polyethylene glycol block copolymers. J. Biomed. Mater. Res. (1999) 47(1):104-110.
137. LI RH, WOZNEY JM: Delivering on the promise of bone morphogenetic proteins. Trends Biotech. (2001) 19(7):255-265.
138. RADOMSKY ML, AUFDEMORTE TB, SWAIN LD et al.: Novel formulation of fibroblast growth factor-2 in a hyaluronan gel accelerates fracture healing in nonhuman primates. J. Orthop. Res. (1999) 17(4):607-614.
139. SELLERS RS, ZHANG R, GLASSON SS et al.: Repair of articular cartilage defects one year after treatment with recombinant human bone morphogenetic protein-2 (rhBMP-2). J. Bone Joint Surg. Am. (2000) 82(2):151-160.
140. KENLEY R, MARDEN L, TUREK T et al.: Osseous regeneration in the rat calvarium using novel delivery systems for recombinant human bone morphogenetic protein-2 (rhBMP-2). J. Biomed. Mater. Res. (1994) 28(10):1139-1147.
141. GAO T, LINDHOLM TS, MARTTINEN A et al.: Composites of bone morphogenetic protein (BMP) and Type IV collagen, coral-derived coral hydroxyapatite, and tricalcium phosphate ceramics. Int. Orthop. (1996) 20(5):321-325.
142. ASAHINA I, WATANABE M, SAKURAI N et al.: Repair of bone defect in primate mandible using a bone morphogenetic protein (BMP)-hydroxyaparite-collagen composite. J. Med. Dent. Sci. (1997) 44(3):63-70.
143. HIGUCHI T, KINOSHITA A, TAKAHASHI K et al.: Bone regeneration by recombinant human bone morphogenetic protein-2 in rat mandibular defects. An experimental model of defect filling. J. Periodontol. (1999) 70(9):1026-1031.
144. PIERSCHBACHER MD, RUOSLAHTI E: Influence of stereochemistry of the sequence Arg-Gly-Asp-Xaa on binding specificity in cell adhesion. J. Biol. Chem. (1987) 262(36):17294-17298.
145. HOLMES TC: Novel peptide-based biomaterial scaffolds for tissue engineering. Trends Biotech. (2002) 20:16-21. A key reference on the improved processes for peptide-based fabrication of biomaterials.
146. YANG XB, ROACH HI, CLARKE NM et al.: Human osteoprogenitor growth and differentiation on synthetic biodegradable structures after surface modification. Bone (2001) 29(6):523-531.
147. HU Y, WINN SR, KRAJBICH I et al.: Porous polymer scaffolds surface-modified with arginine-glycine-aspartic acid enhance bone cell attachment and differentiation in vitro. J. Biomed. Mater. Res. (2003) 64A(3):583-590.
148. QUIRK RA, DAVIES MC, TENDLER SJB et al.: Surface engineering of poly(lactic acid) by entrapment of modifying species. Macromolecules (2000) 33:158-260.
149. HUBBELL J: Bioactive biomaterials. Curr. Opin. Biotechnol. (1999) 10:123-129.
150. SAITO N, OKADA T, HORIUCHI H et al.: A biodegradable polymer as a cytokine delivery system for inducing bone formation. Nat. Biotech. (2001) 19:332-335.
151. DAN N: Synthesis of hierarchial materials. Trends Biotech. (2000) 18:360-374.
152. XU G, WANG W, GROVES JT, HECHT MH: Self-assembled monolayers from a designed combinatorial library of de novo beta-sheet proteins. Proc. Natl. Acad. Sci. USA (2001) 98:3652-3657.
153. MORIZONO K, DE UGARTE DA, ZHU M et al.: Multilineage cells from adipose tissue as gene delivery vehicles. Hum. Gene Ther. (2003) 14(1):59-66.
154. JANKOWSKI RJ, DEASY BM, HUARD J: Muscle-derived stem cells. Gene Ther. (2002) 9(10):642-647.
155. LEE JY, PENG H, USAS A et al.: Enhancement of bone healing based on ex vivo gene therapy using human muscle-derived cells expressing bone morphogenetic protein 2. Hum. Gene Ther. (2002) 13(10):1201-1211.
156. ABE N, LEE YP, SATO M et al.: Enhancement of bone repair with a helper-dependent adenoviral transfer of bone morphogenetic protein-2. Biochem. Biophys. Res. Commun. (2002) 297(3):523-527.
157. KAIHARA S, BESSHO K, OKUBO Y et al.: Over expression of bone morphogenetic protein-3b (BMP-3b) using an adenoviral vector promote the osteoblastic differentiation in C2C12 Cells and augment the bone formation induced by bone morphogenetic protein-2 (BMP-2) in rats. Life Sci. (2003) 72(15):1683-1693.
158. VAN GRIENSVEN M, LOBENHOFFER P, BARKE A et al.: Adenoviral gene transfer in a rat fracture model. Lab. Anim. (2002) 36(4):455-461.
159. PARTRIDGE K, YANG X, CLARKE NM et al.: Adenoviral BMP-2 gene transfer in mesenchymal stem cells: in vitro and in vivo bone formation on biodegradable polymer scaffolds. Biachem. Biophys. Res. Commun. (2002) 292(1):144-152.
160. CHENG SL, LOU J, WRIGHT NM et al.: In vitro and in vivo induction of bone formation using a recombinant adenoviral vector carrying the human BMP-2 gene. Calcif. Tissue Int. (2001) 68(2):87-94.
161. OKUBO Y, BESSHO K, FUJIMURA K et al.: The time course study of osteoinduction by bone morphogenetic peotein-2 via adenoviral vector. Life Sci. (2001) 70(3):325-336.
162. OLMSTED EA, BLUM JS, RILL D et al.: Adenovirus-mediated BMP2 expression in human bone marrow stromal cells. J. Cell Biochem. (2001) 82(1):11-21.
163. TURGEMAN G, PITTMAN DD, MULLER R et al.: Engineered human mesenchymal stem cells: a novel platform for skeletal cell mediated gene therapy. J. Gene Med. (2001) 3(3):240-251.
164. ALDEN TD, BERES EJ, LAURENT JS et al.: The use of bone morphogenetic protein gene therapy in craniofacial bone repair. J. Craniofac. Surg. (2000) 11(1):24-30.